JP2020511468A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511468A5
JP2020511468A5 JP2019550653A JP2019550653A JP2020511468A5 JP 2020511468 A5 JP2020511468 A5 JP 2020511468A5 JP 2019550653 A JP2019550653 A JP 2019550653A JP 2019550653 A JP2019550653 A JP 2019550653A JP 2020511468 A5 JP2020511468 A5 JP 2020511468A5
Authority
JP
Japan
Prior art keywords
disease
fibrosis
syndrome
disorder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511468A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022545 external-priority patent/WO2018170201A1/en
Publication of JP2020511468A publication Critical patent/JP2020511468A/ja
Publication of JP2020511468A5 publication Critical patent/JP2020511468A5/ja
Pending legal-status Critical Current

Links

JP2019550653A 2017-03-16 2018-03-15 Mk2阻害剤の重水素化アナログおよびその使用 Pending JP2020511468A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472022P 2017-03-16 2017-03-16
US62/472,022 2017-03-16
PCT/US2018/022545 WO2018170201A1 (en) 2017-03-16 2018-03-15 Deuterated analogs of mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2020511468A JP2020511468A (ja) 2020-04-16
JP2020511468A5 true JP2020511468A5 (enExample) 2021-04-22

Family

ID=63523341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550653A Pending JP2020511468A (ja) 2017-03-16 2018-03-15 Mk2阻害剤の重水素化アナログおよびその使用

Country Status (4)

Country Link
US (1) US11230551B2 (enExample)
EP (1) EP3596085A4 (enExample)
JP (1) JP2020511468A (enExample)
WO (1) WO2018170201A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015317741B2 (en) 2014-09-17 2020-01-16 Bristol-Myers Squibb Company MK2 inhibitors and uses thereof
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Mk2阻害剤、その合成、およびそれに至るまでの中間体
JP7200120B2 (ja) * 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Mk2阻害剤として有用なヘテロアリール化合物
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
TW202246282A (zh) 2021-02-01 2022-12-01 美商西建公司 Mk2抑制劑、其合成及其中間體
TW202328141A (zh) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 喹啉并呋喃衍生物及其用途
WO2023134764A1 (zh) 2022-01-14 2023-07-20 上海翰森生物医药科技有限公司 含吡啶多环类衍生物、其制备方法和应用
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN115925718A (zh) * 2022-12-27 2023-04-07 瑞石生物医药有限公司 一种四环内酰胺衍生物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2008277676A1 (en) 2007-07-16 2009-01-22 Novartis Ag Heterocyclic compounds useful as MK2 inhibitors
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR20210091832A (ko) 2013-03-15 2021-07-22 셀젠 카르 엘엘씨 Mk2 억제제 및 이의 용도
US9457707B2 (en) * 2014-09-15 2016-10-04 Nissan North America, Inc. Vehicle auxiliary lamp unit
AU2015317741B2 (en) 2014-09-17 2020-01-16 Bristol-Myers Squibb Company MK2 inhibitors and uses thereof
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Mk2阻害剤、その合成、およびそれに至るまでの中間体
JP7200120B2 (ja) * 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Mk2阻害剤として有用なヘテロアリール化合物
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES

Similar Documents

Publication Publication Date Title
JP2020512315A5 (enExample)
JP2020514361A5 (enExample)
JP2020514360A5 (enExample)
ES2988336T3 (es) Un agente antineoplásico 1-((4-(4-fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiquinolin-7-iloxi)metil)ciclopropanamina, su forma cristalina y sus sales
CN109071448B (zh) Ask1抑制剂及其制备方法和应用
CN111471021B (zh) 取代的二氨基甲酰胺和二氨基甲腈嘧啶,其组合物,和用其治疗的方法
JP2024113019A5 (enExample)
JP2020523390A5 (enExample)
JP2013545812A5 (enExample)
JP2022542434A5 (enExample)
JP2019524660A5 (enExample)
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
JP2022531088A5 (enExample)
JP6830888B2 (ja) Jak阻害剤の硫酸水素塩の結晶形およびその製造方法
TW201841910A (zh) 胺吡啶衍生化合物之鹽類、其結晶形及其製備方法
CN111770914A (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
JP2007509043A5 (enExample)
ES2817448T3 (es) Compuestos de pirimidina como inhibidores de quinasas
JP2022521413A5 (enExample)
JP2019507776A (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
TW200835686A (en) Novel compounds 621
ES2340201T3 (es) Moduladores de hexahidro-ciclooctilpirazol cannabinoides.
TW200800211A (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
EP2516420B1 (en) Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
CA2813580A1 (en) Substituted pyridazine carboxamide compounds as kinase inhibitor compounds